Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ABUS
vs
S&P 500
ABUS
S&P 500
Over the past 12 months, ABUS has underperformed S&P 500, delivering a return of -6% compared to S&P 500's +11% growth.
Stocks Performance
ABUS vs S&P 500
Performance Gap
ABUS vs S&P 500
Performance By Year
ABUS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma is a biotechnology company focused on finding treatments for chronic hepatitis B, a liver infection that can become long lasting and serious. It does not sell a broad line of commercial drugs. Instead, it develops experimental medicines and drug-delivery technology, especially programs aimed at shutting down the hepatitis B virus in the body. The company’s main customers, in business terms, are large drugmakers and research partners rather than everyday consumers. Arbutus makes money mainly by advancing its own drug candidates, licensing its technology, and earning payments tied to collaborations or intellectual property. If one of its programs succeeds, it could also share in future product revenue through partnerships or royalties. What makes Arbutus different is that it sits early in the biotech value chain: it creates drug candidates and delivery tools, then works with bigger partners to test, develop, and potentially commercialize them. That means its business depends on scientific success and patent protection more than on manufacturing or selling products itself.
